Peter Diamandis - 20 Jun 2023 Form 4 Insider Report for Vaxxinity, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 20 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2023, 18:32:15 UTC
Prior SEC filing: 16 Jun 2023
Next SEC filing: 03 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Rene Paula Molina, attorney-in-fact for Peter Diamandis

Key filing fact

Peter Diamandis filed Form 4 for Vaxxinity, Inc. on 26 Jun 2023.

Key facts

This page summarizes Peter Diamandis's Form 4 filing for Vaxxinity, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2023, 18:32.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VAXX transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +132,352
Change %
Price: $0.000000
Shares after: 132,352
Date: 20 Jun 2023
Ownership: Direct
Underlying class: Class A common stock
Underlying amount: 132,352
Exercise price: $2.21
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.

Footnote F2

These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date.

Footnote F3

These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.